Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended Access Program of bardoxolone methyl for chronic kidney disease
2018-003253-24Phase 3Terminated
- Sponsor
- Reata Pharmaceuticals
- Start
- Jan 2020
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bardoxolone methyl in chronic kidney disease (CKD), sponsored by Reata Pharmaceuticals. Primary endpoints: Adverse events and serious adverse events, Physical examination changes and 4 more. Started Jan 2020; status: terminated.
02
Drugs
bardoxolone methyl
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2018-003253-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003253-24.